Mekinist (trametinib) | Friends of Cancer Research

You are here

Mekinist (trametinib)

Sponsor: 
Novartis Pharmaceuticals Corp.
Indication: 
In combination with dabrafenib for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options
Category: 
Year: 
2017
Date: 
Oct 23rd
FDA Status: 
FDA Approval
Approval Date: 
May 4th
Approval Year: 
2018